Pendyala Lakshmana, Jabara Refat, Robinson Keith, Chronos Nicolas
Saint Joseph's Translational Research Institute/Saint Joseph's Hospital of Atlanta, Georgia 30342, USA.
J Interv Cardiol. 2009 Feb;22(1):37-48. doi: 10.1111/j.1540-8183.2009.00423.x.
Coronary stent implantation is the second great advance in the treatment of obstructive coronary artery disease since the introduction of balloon catheter angioplasty. However, in-stent restenosis (ISR) caused by neointimal hyperplasia has been a major limitation of stents, occurring in up to 30% of cases. Advances in coronary stent technology both in terms of stent design and function and especially drug-eluting stents (DES) have significantly improved the safety and efficacy of percutaneous coronary intervention (PCI) with stenting, including marked reduction in ISR. This has led to use of DES for increasingly challenging clinical and lesional subsets, with potential for increased risk of stent-associated complications, especially late stent thrombosis (LST). Because restenosis and stent thrombosis are caused by multiple and often interrelated factors, ideal agents for stent coatings should inhibit thrombus formation, inflammatory reaction, and cellular proliferation, while supporting reendothelialization. To avoid undesirable effects of currently applied (durable) polymers, biocompatible, and bioabsorbable polymers as well as DES delivery systems that minimize polymer burden have been produced and tested. Bioabsorbable stents, both polymeric and metallic, have been developed to decrease potential late complications after stent implantation. Novel strategies to address some of these challenges are in various stages of research and development. In this article we outline developments in the field of passive and active stent coatings and evaluate the ongoing role of such coatings in the contemporary era of DES.
冠状动脉支架植入术是自球囊导管血管成形术问世以来,阻塞性冠状动脉疾病治疗领域的第二项重大进展。然而,由新生内膜增生引起的支架内再狭窄(ISR)一直是支架的主要局限性,发生率高达30%。冠状动脉支架技术在支架设计和功能方面,尤其是药物洗脱支架(DES)方面的进展,显著提高了经皮冠状动脉介入治疗(PCI)置入支架的安全性和有效性,包括显著降低ISR。这导致DES被用于越来越具有挑战性的临床和病变亚组,可能增加支架相关并发症的风险,尤其是晚期支架血栓形成(LST)。由于再狭窄和支架血栓形成是由多种且通常相互关联的因素引起的,理想的支架涂层药物应抑制血栓形成、炎症反应和细胞增殖,同时支持内皮再形成。为避免目前应用的(耐用)聚合物产生不良影响,已生产并测试了生物相容性、可生物吸收的聚合物以及使聚合物负担最小化的DES递送系统。已经开发出聚合物和金属材质的可生物吸收支架,以减少支架植入后潜在的晚期并发症。应对其中一些挑战的新策略正处于不同的研发阶段。在本文中,我们概述了被动和主动支架涂层领域的进展,并评估了此类涂层在当代DES时代的持续作用。